Semaglutide Demonstrates Groundbreaking Cardiovascular Benefits with 29% Risk Reduction

Emerging clinical evidence indicates this revolutionary medication not only effectively lowers blood sugar and promotes weight loss but also provides powerful protection for cardiovascular disease patients without diabetes.

At the prominent European Society of Cardiology 2025 Congress, researchers presented breakthrough data on semaglutide. The STEER real-world study results revealed that semaglutide reduces the risk of major adverse cardiovascular events by 29% in overweight or obese patients with established cardiovascular disease but without diabetes.

Under ideal dosing conditions, patients consistently treated with semaglutide demonstrated up to 57% risk reduction, significantly outperforming comparative medications. This establishes semaglutide as the first GLP-1 medication proven to provide cardiovascular benefits for obese patients with cardiovascular disease but without diabetes.

01 Major Cardiovascular Breakthrough

Obesity is an independent risk factor for cardiovascular disease, directly contributing to increased cardiovascular morbidity, mortality, and hospitalization rates. Approximately 21 million people worldwide die from cardiovascular diseases each year, making it the leading cause of disability and mortality.

The STEER study, a retrospective observational real-world analysis, evaluated the effectiveness of semaglutide 2.4 mg compared to other medications in preventing major adverse cardiovascular events (MACE) in overweight or obese patients with established cardiovascular disease but without diabetes.

The study enrolled patients aged ≥45 years, with 10,625 participants in each group. To ensure comparability, researchers used propensity score matching to compare patients with similar characteristics receiving semaglutide versus other treatments.

02 From Glucose Control to Cardiovascular Protection

Semaglutide is a long-acting GLP-1 receptor agonist that works by stimulating insulin secretion, suppressing glucagon release, and delaying gastric emptying to lower blood glucose, while demonstrating significant weight loss effects.

In related clinical studies, the semaglutide 1.0 mg dose group achieved a 1.5% reduction in glycated hemoglobin, significantly outperforming comparator medications. Regarding weight reduction, the treatment group showed an average weight loss of 4.5 kg, providing additional benefits for patients with diabetes who are overweight or obese.

03 Multidimensional Therapeutic Benefits

Beyond cardiovascular breakthroughs, semaglutide recently received accelerated FDA approval for treating metabolic dysfunction-associated steatohepatitis (MASH). This marks the first weight-loss medication approved for MASH, representing a significant advancement in liver disease treatment.

Phase III clinical trial data showed that at week 72, 36.8% of semaglutide-treated patients achieved liver fibrosis improvement without worsening steatohepatitis, while 62.9% achieved steatohepatitis resolution without worsening fibrosis. Placebo groups showed 22.4% and 34.3% improvements, respectively.

As a glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide improves metabolism through weight loss, anti-inflammatory effects, and enhanced insulin sensitivity, reducing liver fat accumulation, alleviating inflammation, and slowing fibrosis progression.

04 Evolving Competitive Landscape

Semaglutide's latest data is reshaping the competitive landscape of the GLP-1 market. The STEER study has successfully shifted the competitive focus toward "cardiovascular protection," where the medication demonstrates particular strength.

Pharmaceutical industry analysts note the exceptional value of this newly released data. Semaglutide not only demonstrates overwhelming efficacy advantages but also expands the therapeutic battlefield from diabetes management and weight loss to the broader field of cardiovascular disease prevention by focusing on patients without diabetes.

With the SELECT study (focusing on diabetic patients) and the current STEER research (focusing on non-diabetic patients), semaglutide has established a comprehensive and robust database for cardiovascular benefits, creating significant barriers for competitors.

05 Accelerated Domestic Market Development

Given semaglutide's substantial market potential, multiple pharmaceutical companies have initiated development of semaglutide biosimilars. Recently, another company's semaglutide injection application was accepted, becoming the eighth domestic manufacturer to submit marketing applications for semaglutide.

Currently, marketing applications from seven companies have been accepted, submitted under various categories. Over 20 semaglutide products have entered clinical stages in domestic markets, indicating strong industry interest in this emerging therapeutic area.

06 Broad Future Applications

Representative semaglutide products generated approximately $16.5 billion in global revenue in the first half of the year, making it one of the world's top-selling medications. The weight-loss version of semaglutide injection sales increased by 78% year-over-year.

Future competition will evolve beyond simple "weight loss contests" toward more comprehensive and integrated approaches. The focus will shift from "weight reduction percentages" to comprehensive benefits including cardiovascular protection, renal benefits, MASH treatment, and sleep apnea improvement.

Oral formulations, extended injection intervals (such as monthly dosing), and reduced side effects will be critical factors in next-generation product competition. Combining GLP-1 medications with other mechanism-based drugs may achieve synergistic effects, potentially representing the ultimate path to efficacy ceilings.

With accumulating clinical evidence, semaglutide has evolved from a simple glucose-lowering medication to a comprehensive metabolic syndrome management drug.

Global populations include hundreds of millions of obese patients with cardiovascular problems. Semaglutide's latest cardiovascular benefit data provides solid evidence for entering this massive market.

For healthcare providers and payers, improvements in cardiovascular outcomes are becoming more compelling indicators than simple weight loss percentages. With first-mover advantages, semaglutide is securing priority positions in clinical guidelines and physician preferences.